• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Amgen British Columbia

Member Profile

Amgen British Columbia Inc., one of several research facilities operated by Amgen Inc., specializes in the discovery and development of human therapeutic antibodies. The research center, located in Burnaby, became part of Amgen with Amgen’s acquisition of Abgenix, Inc. in April 2006. It employs approximately 95 people, including research scientists and a small support staff. Amgen is headquartered in the United States and has more than 21,000 staff members worldwide. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing novel medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, migraine, osteoporosis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Therapeutics
  • Wellness solutions
Company Stage Public Company
Stock Ticker AMGN - NASDAQ

Member Profile

Biotechnology, Therapeutics

Amgen British Columbia

Silver Sponsor

Amgen logo blue
  • Website www.amgen.ca
  • Phone +1 (604) 415 1800
  • Address
    7990 Enterprise Street
    Burnaby, BC
    V5A 1V7
  • Leadership Contact
    Brian Heath, Vice President & General Manager
    Follow us:
  • Twitter
  • Facebook
  • LinkedIn
  • Instagram
  • News
  • Jobs

September 12, 2022

Lumakras® (Sotorasib) Combined with Vectibix® (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients with Kras g12c-Mutated Metastatic Colorectal Cancer

August 29, 2022

New Amgen Data at Esc 2022 Show Long-Term Ldl-C Lowering With Repatha® (Evolocumab) was Well-Tolerated for More Than 8 Years

August 8, 2022

Amgen Presents New Tarlatamab Clinical Data at WCLC 2022

April 10, 2022

Lumakras® (Sotorasib) Codebreak 100 Study Shows Two-Year Overall Survival Of 32.5% In Patients With Kras G12c-Mutated Advanced Non-Small Cell Lung Cancer

January 11, 2022

Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel Rna Degrader Small Molecule Therapeuticsevent Details

No current content.

  • Twitter
  • Linkedin
Tweets by Amgen British Columbia
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us